Wambolt & Associates, LLC Abb Vie Inc. Transaction History

Wambolt & Associates, LLC

$366 Million
Q3 2024

A detailed history of Wambolt & Associates, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Wambolt & Associates, LLC holds 29,060 shares of ABBV stock, worth $4.93 Million. This represents 1.57% of its overall portfolio holdings.

Number of Shares

29,060

Previous 28,495 1.98%

Holding current value

$4.93 Million

Previous $4.89 Million 17.41%

% of portfolio

1.57%

Previous 1.43%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$163.84 - $199.33 $92,569 - $112,621	565 Added 1.98%	29,060 $5.74 Million
Q2 2024 Aug 07, 2024	BUY	$154.79 - $180.76 $146,740 - $171,360	948 Added 3.44%	28,495 $4.89 Million
Q1 2024 Apr 30, 2024	BUY	$159.82 - $182.1 $15,502 - $17,663	97 Added 0.35%	27,547 $5.02 Million
Q4 2023 Feb 07, 2024	BUY	$137.6 - $154.97 $54,627 - $61,523	397 Added 1.47%	27,450 $4.25 Million
Q3 2023 Nov 06, 2023	BUY	$133.59 - $154.65 $85,497 - $98,976	640 Added 2.42%	27,053 $4.03 Million
Q2 2023 Aug 02, 2023	SELL	$132.51 - $164.9 $6,625 - $8,245	-50 Reduced 0.19%	26,413 $3.56 Million
Q1 2023 May 05, 2023	BUY	$144.61 - $166.54 $83,729 - $96,426	579 Added 2.24%	26,463 $4.22 Million
Q4 2022 Jan 31, 2023	BUY	$138.31 - $165.87 $53,387 - $64,025	386 Added 1.51%	25,884 $4.19 Million
Q3 2022 Oct 18, 2022	BUY	$134.21 - $153.93 $13,018 - $14,931	97 Added 0.38%	25,498 $3.42 Million
Q2 2022 Aug 01, 2022	BUY	$137.62 - $174.96 $102,114 - $129,820	742 Added 3.01%	25,401 $3.89 Million
Q1 2022 May 10, 2022	BUY	$131.98 - $163.75 $200,873 - $249,227	1,522 Added 6.58%	24,659 $4.01 Million
Q4 2021 Feb 08, 2022	BUY	$107.43 - $135.93 $115,379 - $145,988	1,074 Added 4.87%	23,137 $3.13 Million
Q3 2021 Oct 20, 2021	BUY	$106.4 - $120.78 $218,652 - $248,202	2,055 Added 10.27%	22,063 $2.41 Million
Q2 2021 Aug 13, 2021	BUY	$105.21 - $117.21 $246,822 - $274,974	2,346 Added 13.28%	20,008 $2.29 Million
Q1 2021 Apr 19, 2021	BUY	$102.3 - $112.62 $275,903 - $303,736	2,697 Added 18.02%	17,662 $1.92 Million
Q4 2020 Jan 19, 2021	BUY	$80.49 - $108.67 $176,595 - $238,421	2,194 Added 17.18%	14,965 $1.6 Million
Q3 2020 Nov 04, 2020	BUY	$85.91 - $100.83 $229,293 - $269,115	2,669 Added 26.42%	12,771 $1.12 Million
Q2 2020 Jul 23, 2020	BUY	$73.37 - $98.18 $136,468 - $182,614	1,860 Added 22.57%	10,102 $992,000
Q1 2020 May 11, 2020	BUY	$64.5 - $97.79 $165,507 - $250,929	2,566 Added 45.21%	8,242 $628,000
Q4 2019 Feb 10, 2020	SELL	$72.13 - $90.25 $144 - $180	-2 Reduced 0.04%	5,676 $503,000
Q3 2019 Oct 15, 2019	SELL	$62.98 - $75.72 $14,170 - $17,037	-225 Reduced 3.81%	5,678 $430,000
Q2 2019 Jul 26, 2019	BUY	$65.7 - $83.98 $60,246 - $77,009	917 Added 18.39%	5,903 $429,000
Q1 2019 Apr 11, 2019	SELL	$77.14 - $90.79 $11,031 - $12,982	-143 Reduced 2.79%	4,986 $412,000
Q4 2018 Jan 29, 2019	BUY	$77.85 - $96.01 $399,292 - $492,435	5,129 New	5,129 $473,000

Others Institutions Holding ABBV

# of Institutions

3,817

Shares Held

1.25B

Call Options Held

13M

Put Options Held

10M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $300B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wambolt & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wambolt & Associates, LLC with notifications on news.

Account

Wambolt & Associates, LLC Abb Vie Inc. Transaction History